Bayer Oncology Medical Affairs Department is interested in receiving and reviewing grant applications to support appropriate programs which cover the following area of interest:
Therapeutic Areas/Disease States:
Gynecological Cancers including Ovarian, Endometrial, Cervical, Fallopian Tube, etc.
Intended Audience: Oncologists, Pathologists, Surgeons, Gynecologists, Community HCPs, Patients/Caregivers
Areas of interest based on referenced literature:
- Treatment and management of Gynecological Cancer including Ovarian Cancer, Endometrial, Cervical, Fallopian Tube etc.
- Education on biomarker driven testing strategies/appropriate testing modalities
- Role of NTRK gene fusion and impact of TRK gene fusion/TRK testing in treatment algorithms for Gynecological Cancers including Ovarian Cancer, Endometrial, Cervical, Fallopian Tube etc.
- Understanding of efficacy and safety profiles of approved TRK inhibitors in Gynecological Cancers
- Multi-disciplinary approach to precision medicine
- Understanding and management of adverse event profiles
All submissions for CE/CME support must be consistent with the ACCME guidelines and contain supporting documents that should include:
- Needs assessment
- Educational design and rationale for selection (where applicable)
- Learning objectives
- Proposed faculty
- Participant recruitment plan (where applicable)
- Outcomes strategy/plan (required on a quarterly basis)
- Detailed budget
- Copy of most recent accreditation letter and status
- Sample of other program(s) in similar therapeutic area
Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a Bayer Medical Affairs representative to audit live programs
- Share activity data and outcomes metrics within 30 days of their availability
- Drilon A, Laetsch TW, Kummar S et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-9. (link)
- Hong, D et al. Long-term efficacy and safety of Larotrectinib in an integrated database of patients with TRK fusion cancer. ASCO 2021 presentation.
- Kummar, S et al. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancers receiving Larotrectinib. Journal of Clinical Oncology 37, 2019 (suppl; abstr 6602) (link)
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cervical, Ovarian, Uterine Neoplasms
- Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, Jin DX, Newberg JY, Fabrizio D, Veronese L, Thomas M, de Braud F. Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021 Sep 17;5(1):86. doi: 10.1038/s41698-021-00222-y. https://pubmed.ncbi.nlm.nih.gov/34535754/